Is metformin a miracle or a menace in COVID-19 patients with type 2 diabetes?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

1. One year into the clash of pandemics of diabetes and COVID-19: Lessons learnt and future perspectives.Journal of diabetes investigation · 2022
   Article
2. The management of type 2 diabetes before, during and after Covid-19 infection: what is the evidence?Cardiovascular diabetology · 2021
   Article
3. The COVID-19 world - Are we there yet?Journal of diabetes investigation · 2021
   Article

Corrections and comments

• Comment on
  Metformin Is Associated with Higher Incidence of Acidosis, but Not Mortality, in Individuals with COVID-19 and Pre-existing Type 2 Diabetes.2020

Authors and funding

2 authors at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as